BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » FUJIFILM Acquires Cellular Dynamics International (CDI)
Stem Cell Industry Acquisition between CDI and Fuji Film

FUJIFILM Acquires Cellular Dynamics International (CDI)

April 2, 2015 By Cade Hildreth (CEO) Leave a Comment

CDI / FUJIFILMTOKYO and MADISON, Wis., March 30, 2015 — FUJIFILM Holdings Corporation (President: Shigehiro Nakajima) (“Fujifilm”) and Cellular Dynamics International, Inc. (CEO: Robert Palay) (“CDI”), a leading developer and manufacturer of fully functioning human cells in industrial quantities, announced that the two companies have entered into a agreement whereby Fujifilm will acquire CDI via an all-cash tender offer to be followed by a second step merger.

Discover class-defining bioproduction tools.

FUJIFILM Acquires CDIFujifilm aims to acquire all issued and outstanding shares of CDI’s common stock for $16.5 per share or approximately $ 307 million (on a fully diluted basis). The offer represents a premium of 108% to CDI’s closing price on March 27. Upon completion of the transaction, CDI will continue to run its operations in Madison, Wisconsin and Novato, California as a consolidated subsidiary of Fujifilm.

CDI was founded in 2004 and listed on NASDAQ in July 2013. The company had global revenues of $16.7 million in 2014 and currently has 155 employees. CDI’s technology platform enables the production of high-quality fully functioning human cells, including induced pluripotent stem cells (iPSCs), on an industrial scale. CDI’s proprietary iCell product catalogue also includes 12 iPSC based cell types, including: iCell Cardomyocytes, iCell Hepatocytes, and iCell Neurons.

bitbio

Fujifilm Acquires CDI to Expand Its Regenerative Medicine Portfolio

Stemming from knowledge about photographic films, Fujifilm has developed highly-biocompatible recombinant peptides that can be shaped into a variety of forms for use as a cellular scaffold in regenerative medicine when used in conjunction with CDI’s products. Fujifilm has been strengthening its presence in the regenerative medicine field over several years, including by acquiring a majority of shares of Japan Tissue Engineering Co. in December 2014.

Fujifilm aquisition of CDI will position it to gain dominance in the area of iPS cell-based drug discovery support services. Fujifilm will also benefit from strategically combining CDI’s iPS cell technology with Fujifilm’s expertise in material science, engineering, and quality management systems.

iPSC-derived cardiomyocte therapy

Read the full Press Release now →

Pluristyx

About Us

BioInformant is the first and only market research firm to specialize in the stem cell industry. BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Serving industry leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.

Rate this post

Filed Under: iPS Cells Tagged With: acquisition, CDI, FUJIFILM, iPSC, market news

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

PolarityTE RMAT

PolarityTE Announces FDA RMAT Awarded to Its Designation Granted to SkinTE®

Advanced Therapy | What is a RMAT Designation (and Who Has One)?

What Is An RMAT? List of Publicly Announced RMAT Designations (64)

i-peaces-cell-manufacturing

I Peace accelerates allogeneic iPSC-derived cell therapies with a high throughput method to identify a large number of donors with specific HLA haplotypes

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.